tiprankstipranks
Advertisement
Advertisement
AbbVie Targets Rare Blood Disorder With New Phase 3 Etentamig Trial Plan
PremiumCompany AnnouncementsAbbVie Targets Rare Blood Disorder With New Phase 3 Etentamig Trial Plan
7d ago
AbbVie Expands Its IBD Pipeline With New Phase 2 Basket Trial in Crohn’s and Ulcerative Colitis
Premium
Company Announcements
AbbVie Expands Its IBD Pipeline With New Phase 2 Basket Trial in Crohn’s and Ulcerative Colitis
7d ago
AbbVie submits Skyrizi application to the EMA
Premium
The Fly
AbbVie submits Skyrizi application to the EMA
8d ago
AbbVie Targets Pediatric Alopecia With New Phase 3 Trial: What Investors Should Watch
PremiumCompany AnnouncementsAbbVie Targets Pediatric Alopecia With New Phase 3 Trial: What Investors Should Watch
14d ago
AbbVie’s Emraclidine Schizophrenia Study Ends Early: What Investors Need to Know Now
Premium
Company Announcements
AbbVie’s Emraclidine Schizophrenia Study Ends Early: What Investors Need to Know Now
14d ago
AbbVie Targets Next-Gen BOTOX Combo With New Glabellar Lines Study
Premium
Company Announcements
AbbVie Targets Next-Gen BOTOX Combo With New Glabellar Lines Study
15d ago
AbbVie upgraded to Outperform from Peer Perform at Wolfe Research
PremiumThe FlyAbbVie upgraded to Outperform from Peer Perform at Wolfe Research
18d ago
Apogee Therapeutics price target raised to $135 from $81 at Truist
Premium
The Fly
Apogee Therapeutics price target raised to $135 from $81 at Truist
18d ago
AbbVie Steps Deeper Into Alzheimer’s: What the ABBV-1758 Trial Means for Investors
Premium
Company Announcements
AbbVie Steps Deeper Into Alzheimer’s: What the ABBV-1758 Trial Means for Investors
21d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100